Affordable Access

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

Authors
  • Pincus, T
  • Ferraccioli, G
  • Sokka, T
  • Larsen, A
  • Rau, R
  • Kushner, I
  • Wolfe, F
Type
Published Article
Journal
Rheumatology (Oxford, England)
Publication Date
Dec 01, 2002
Volume
41
Issue
12
Pages
1346–1356
Identifiers
PMID: 12468813
Source
Medline
License
Unknown

Abstract

Earlier reports, including a comprehensive 1983 review, had indicated that slowing of radiographic progression was relatively unusual in treatment of rheumatoid arthritis (RA) using traditional disease modifying anti-rheumatic drugs. However, in recent years, slowing of radiographic progression has been documented in a number of clinical trials, as well as long-term observational studies, with use of (in alphabetical order) adalimumab, anakinra, corticosteroids, cyclophosphamide, cyclosporin, etanercept, gold salts, infliximab, leflunomide, methotrexate and sulphasalazine. At this time, disease modification is a realistic goal in the clinical care of patients with RA. Documentation of improved long-term outcomes requires long-term observational data over 5-20 yr to supplement data from randomized controlled clinical trials over 6-24 months.

Report this publication

Statistics

Seen <100 times